The "Breast Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price, Approved Drug Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The ...

Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration ...

(GLOBE NEWSWIRE) -- (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

DUBLIN--(BUSINESS WIRE)--The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

A review of JADER and FAERS databases identified common adverse effects for 3 antibody-drug conjugates with the same type of payload.

DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ResearchAndMarkets.com ...

| According to DataM Intelligence AUSTIN, Texas and TOKYO, Oct. 27, 2025 /PRNewswire/ -- The Antibody-Drug Conjugates (ADC) Market Size was valued at around US $11.9 billion in 2024, the market is ...

NEOK Bio, Inc., a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving ...

Antibody-drug conjugates (ADCs) have revolutionized the oncology field, offering targeted cancer treatments that improve efficacy without adversely affecting healthy cells. 1 ADCs’ potential extends ...

Researchers identified predictors of immunotherapy response in advanced bladder cancer, including tumor mutational burden and APOBEC mutational signature. The FDA-approved combination of Keytruda and ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...